Histone deacetylases and their inhibitors: New implications for asthma and chronic respiratory conditions

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 1, 2014, Pages 44-48

  Royce, Simon G ^a,b   Karagiannis, Tom C ^b  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

allergic airways disease; asthma; histone deacetylase inhibitor; inflammatory lung condition; trichostatin A

Indexed keywords

ACETIC ACID DERIVATIVE; BLEOMYCIN; DNA; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LYSINE; SIRTUIN;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; GENE EXPRESSION; HUMAN; HYDROLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; REVIEW; AIRWAY REMODELING; ANIMAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATION; LUNG; METABOLISM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

AIRWAY REMODELING; ANIMALS; ASTHMA; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; INFLAMMATION; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84892363964     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000029     Document Type: Review

References (42)

1. Bouchecareilh M, Balch WE. Proteostasis, an emerging therapeutic paradigm for managing inflammatory airway stress disease. Curr Mol Med 2012; 12:815-826
2. Marks PA. Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 2010; 1799:717-725
3. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010; 19:1049-1066
4. Royce SG, Ververis K, Karagiannis TC. Histone deacetylase inhibitors: Can we consider potent antineoplastic agents for the treatment of asthma? Ann Clin Lab Sci 2012; 42:338-345
5. Sundar IK, Yao H, Rahman I. Oxidative stress and chromatin remodeling in chronic obstructive pulmonary disease and smoking-related diseases. Antioxid Redox Signal 2013; 18:1956-1971
6. Do-Umehara HC, Chen C, Urich D, et al. Suppression of inflammation and acute lung injury by Miz1 via repression of C/EBP-delta. Nat Immunol 2013; 14:461-469
7. Wang Y, Tian Y, Morley MP, et al. Development and regeneration of Sox2endoderm progenitors are regulated by a Hdac1/2-Bmp4/Rb1 regulatory pathway. Dev Cell 2013; 24:345-358
8. Barnes PJ. Development of new drugs for COPD. Curr Med Chem 2013; 20:1531-1540
9. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013; 131:636-645
10. Hakim A, Adcock IM, Usmani OS. Corticosteroid resistance and novel antiinflammatory therapies in chronic obstructive pulmonary disease: Current evidence and future direction. Drugs 2012; 72:1299-1312
11. Butler CA, McQuaid S, Taggart CC, et al. Glucocorticoid receptor beta and histone deacetylase 1 and 2 expression in the airways of severe asthma. Thorax 2012; 67:392-398
12. Hou XX, Shi GC, Wan HY, et al. Characteristics of histone deacetylase 9 in peripheral blood of patients with bronchial asthma. Zhonghua Jie He He Hu Xi Za Zhi 2012; 35:340-344
13. Ortiz JL, Milara J, Lluch J, et al. Phosphodiesterase-4 inhibition improves corticosteroid insensitivity in pulmonary endothelial cells under oxidative stress. Allergy 2013; 68:64-73
14. Qu Y, Yang Y, Ma D, et al. Expression level of histone deacetylase 2 correlates with occurring of chronic obstructive pulmonary diseases. Mol Biol Rep 2013; 40:3995-4000
15. Winkler AR, Nocka KN, Williams CM. Smoke exposure of human macrophages reduces HDAC3 activity, resulting in enhanced inflammatory cytokine production. Pulm Pharmacol Ther 2012; 25:286-292
16. Nie YC, Wu H, Li PB, et al. Characteristic comparison of three rat models induced by cigarette smoke or combined with LPS: To establish a suitable model for study of airway mucus hypersecretion in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2012; 25:349-356
17. Huang SK, Scruggs AM, Donaghy J, et al. Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. Cell Death Dis 2013; 4:e621
18. Korfei M, Buchwald M, Klepetko W, et al. Aberrant expression and activity of histone deacetylases (HDACs) in lungs of patients with sporadic Idiopathic Pulmonary Fibrosis (IPF). Pneumologie 2012; 66:A506
19. Kallsen K, Andresen E, Heine H. Histone deacetylase (HDAC) 1 controls the expression of beta defensin 1 in human lung epithelial cells. PloS ONE 2012; 7:e50000
20. Liu Q, Liu J, Roschmann KI, et al. Histone deacetylase inhibitors up-regulate LL-37 expression independent of toll-like receptor mediated signalling in airway epithelial cells. J Inflamm (Lond) 2013; 10:15
21. Biswal S, Thimmulappa RK, Harvey CJ. Experimental therapeutics of Nrf2 as a target for prevention of bacterial exacerbations in COPD. Proc Am Thorac Soc 2012; 9:47-51
22. Chen Y, Watson AM, Williamson CD, et al. Glucocorticoid receptor and histone deacetylase-2 mediate dexamethasone-induced repression of MUC5AC gene expression. Am J Respir Cell Mol Biol 2012; 47:637-644
23. Zhao L, Chen CN, Hajji N, et al. Histone deacetylation inhibition in pulmonary hypertension: Therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 2012; 126:455-467
24. Cantoni S, Galletti M, Zambelli F, et al. Sodium butyrate inhibits plateletderived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition. FEBS J 2013; 280:2042-2055
25. Shi YL, Gu J, Park JY, et al. Histone deacetylases inhibitor Trichostatin A ameliorates DNFB-induced allergic contact dermatitis and reduces epidermal Langerhans cells in mice. J Dermatol Sci 2012; 68:99-107
26. Kim Y, Kim K, Park D, et al. Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein. J Biol Chem 2012; 287:25844-25859
27. Kienzler AK, Rizzi M, Reith M, et al. Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid. J Allergy Clin Immunol 2013; 131:1695-1699; e1699
28. Banerjee A, Trivedi CM, Damera G, et al. Trichostatin A abrogates airway constriction, but not inflammation, in murine and human asthma models. Am J Respir Cell Mol Biol 2012; 46:132-138
29. Bouchecareilh M, Hutt DM, Szajner P, et al. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of alpha1-antitrypsin deficiency. J Biol Chem 2012; 287:38265-38278
30. Yang Q, Lu Z, Ramchandran R, et al. Pulmonary artery smooth muscle cell proliferation and migration in fetal lambs acclimatized to high-altitude longterm hypoxia: Role of histone acetylation. Am J Physiol Lung Cell Mol Physiol 2012; 303:L1001-L1010
31. Royce SG, Dang W, Yuan G, et al. Effects of the histone deacetylase inhibitor, trichostatin A, in a chronic allergic airways disease model in mice. Arch Immunol Ther Exp 2012; 60:295-306
32. Davies ER, Haitchi HM, Thatcher TH, et al. Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis. Am J Respir Cell Mol Biol 2012; 46:687-694
33. Liu T, Ullenbruch M, Choi YY, et al. Telomerase and telomere length in pulmonary fibrosis. Am J Respir Cell Molr Biol 2013; 49:260-268
34. Yao H, Rahman I. Perspectives on translational and therapeutic aspects of SIRT1 in inflammaging and senescence. Biochem Pharmacol 2012; 84:1332-1339
35. Xu B, Chen H, Xu W, et al. Molecular mechanisms of MMP9 overexpression and its role in emphysema pathogenesis of Smad3-deficient mice. Am J Physiol Lung Cell Mol Physiol 2012; 303:L89-L96
36. Yao H, Chung S, Hwang JW, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest 2012; 122:2032-2045
37. Wu Z, Liu MC, Liang M, Fu J. Sirt1 protects against thrombomodulin downregulation and lung coagulation after particulate matter exposure. Blood 2012; 119:2422-2429
38. Isajevs S, Strazda G, Kopeika U, Taivans I. Different patterns of lung sirtuin expression in smokers with and without chronic obstructive pulmonary disease. Medicina (Kaunas) 2012; 48:552-557
39. Warburton D, Shi W, Xu B. TGF-beta-Smad3 signaling in emphysema and pulmonary fibrosis: An epigenetic aberration of normal development? Am J Physiol Lung Cell Mol Physiol 2013; 304:L83-L85
40. Ichikawa T, Hayashi R, Suzuki K, et al. Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthma. Respirology 2013; 18:332-339
41. Rieder SA, Nagarkatti P, Nagarkatti M. Multiple anti-inflammatory pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin B-induced lung injury. Br J Pharmacol 2012; 167:1244-1258
42. Royce SG, Dang W, Gao Y, et al. Resveratrol has protective effects against airway remodeling and airway inflammation in a murine model of allergic airways disease. Pathobiol Aging Age Relat Dis 2011; 1:7134